As previously reported, Piper Sandler analyst David Amsellem downgraded Eagle Pharmaceuticals to Underweight from Neutral with a price target of $17, down from $26, following the company’s Q2 report. Though the company having raised its FY20 adjusted EBITDA and EPS guidance “is not lost on us,” the firm says it “continues to struggle” with the longer-term EBITDA trajectory given what it views as “challenging dynamics on multiple fronts,” including declining contribution from bendamustine products and sluggish uptake of new products Barhemsys and Byfavo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EGRX:
- Eagle Pharmaceuticals Reports Second Quarter 2023 Results
- EGRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
- Eagle Pharma raises FY23 adjusted EPS view to $4.40-$4.70 from $4.20-$4.53
- Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance